Michael Vlaicu

A young and savvy, yet experienced and accomplished investments mogul since ´01; Michael has amassed a fortune as a private self investor. Recently starting his own successful blog and turning it in to a corporation — MiV Investments Inc., a company offering advice to thousands of people worldwide and attracting contracts from various reputable sources. The financial news portal can be found at www.StocksHaven.com. Michael has reached Expert Stock Analyst status from a variety of accredited publications.

Articles by Michael Vlaicu

A New Star in Cancer Therapy (OTC BB:ADXS)
For more financial news visit, www.TheMarketFinancial.com
World Infertility Device Leader (OTC BB: IVOB)
The Market Financial Analyzes Invo's Market Potential (OTC BB: IVOB)
Provision Interactive Set to Revolutionize the Billion Dollar Advertising Market (OTC:PVHO.OB)
Provision Interactive Brings 3D Tactile Holographic Advertising to the Market (OTC:PVHO.OB)
Burning the Calories with CardioCor (PINK:CDOI.PK)
CardioCor Helping Americans Lose Weight Faster (PINK:CDOI.PK)
Awaiting IND Targetting a Twenty-Eight Billion Dollar Market (OTC:ACTC.OB)
Pending IND Targetting a 28B AMD Market (OTC:ACTC.OB)
Empowering Alternative Renewable Energy from Disposable Waste (PINK:WTWO.PK)
W2 Energy Redefines the Renewable Alternative Energy Industry (PINK:WTWO.PK)
A New Spotlight on Diverse Media Group (PINK:DVME.PK)
A New Star Emerges in Diverse Media Group (PINK:DVME.PK)
XTend Medical Set to Redefine Cancer Detection With Nanotechnology (PINK:XMDC.PK)
XTend Medical Looks Towards Breakthrough Cancer Detection Nanotechology (PINK:XMDC.PK)
Holiday Season May Bring Renewed Interest in BizAuctions (OTC:BZCN.OB)
BizAuctions Looks to Rebound During Holiday Season (OTC:BZCN.OB)
AVAX Currently Pending Clinical Trials News for its Pipeline (OTC:AVXT.PK)
News Awaits for AVAX's Phase II and Phase III Clinical Trials (OTC:AVXT.PK)
A Renewed Sense of Optimism in Paradigm Medical (OTC:PDMI.PK)
Paradigm Medical Rebounds as Investors Await Four New Devices (OTC:PDMI.PK)
FDA Medical Device: Non-Invasive Cervical Cancer Detection (OTC:GTHP.OB)
Guided Therapeutics Targets One Billion Dollar Market (OTC:GTHP.OB)
Why Soligenix Will be Successful (OTC:SNGX.OB)
Soligenix Aims for Bright Future Ahead (OTC:SNGX.OB)
FDA Play: Soligenix, Poised for a Stellar Comeback (OTC:SNGX.OB)
FDA Play: Massive Potential, Undervalued, Gaining Momentum (OTC:SNGX.OB)
Can American Scientific be the Next Big Thing? (PINK:ASFX)
American Scientific Resources (PINK:ASFX.PK) Looks to Rise Up
An Exciting Upcoming 4Q09 for NeoPharm (OTC:NEOL)
NeoPharm Inc. (OTC:NEOL) Looks For Bright News in 4Q09
Biovest Inches Closer to Cancer Vaccine NDA Filing (OTC:BVTI)
NDA Filing Nears for Biovest (OTC:BVTI)
FDA Play: Redefining Breast Cancer Detection (OTC:LLBO)
LifeLine BioTechnologies Looks Ahead of FDA Decision (OTC:LLBO)
Taking Cancer Treatment to a New Level (OTC:PVCT)
Provectus Takes Aim to Treat Five Types of Cancer (OTC:PVCT)
New Pain Treatment Triumphs Morphine (OTC:NPHC)
StocksHaven Investments profiles Nutra Pharma Inc.(OTC:NPHC)
FDA Play: Revolutionary Medical Device (OTC:IMGG)
StocksHaven Investments Profiles Imaging3's (OTC:IMGG) FDA Seeking Medical Device
GenVec's TNFerade Nears NDA Status (NASDAQ:GNVC)
StocksHaven Investments profiles GenVec and it's lead product TNFerade (NASDAQ:GNVC)
Muscle Flex Inc: A Rare Investment Opportunity (OTC:MFLI)
StocksHaven Investments Takes a Closer Look at Muscle Flex Inc. (OTC:MFLI)
Three Blockbuster Drugs Seeking NDA (AMEX:AEN)
Adeona Prepares Three Drugs for NDA Submission (AMEX:AEN)
Advanced Healing Now Possible (OTC:DSCI)
Derma Sciences (OTC:DSCI) targets a prescription drug market that is 5x its present market cap
Giving Birth to a Profitable Company (OTC:IVOB)
StocksHaven Investments takes a closer look at INVO BioScience Inc.
Lung Cancer Medical Breakthrough (OTC:BMOD)
StocksHaven Investments profiles Biomoda Inc. (OTC:BMOD)
CEO Reaffirms Positive Future Outlook
StocksHaven Investments Engagee in a Conversation with SymPowerco Corp CEO, John Davenport (PINK:SYMW)
Investment Performance Update
StocksHaven Investments takes a closer look at the past performances in (OTC:SPNG), (NASDAQ:MESA), (AMEX:HEB), (OTC:ACCP), (OTC:NEPH), (OTC:BIEL), (NASDAQ:TESTR), (PINK:HTDS),(NASDAQ:SOMX),(PINK:SYMW)
Pain for Pleasure with Javelin Pharmaceuticals (AMEX:JAV)
StocksHaven Investments news portal takes a closer look at Javelin Pharmaceuticals (AMEX:JAV), which hopes its three drugs in Phase III, one of which already has European approval will make a splash within the pain medication market.
Uncovering a Diamond in the Rough, SymPower (PINK:SYMW)
StocksHaven Investments news portal takes a closer look at SymPowerco Corp. (PINK:SYMW), which hopes its majority-owned subsidiary, Polygenic Power Systems alongside the recent government grant will propel it into future success.
Second Time´s a Charm for Somaxon (NASDAQ:SOMX)
StocksHaven Investments news portal takes a closer look at Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), which hopes its drug, Silenor will be approved for the treatment of insomnia.
Multiple Paths for Success (PINK:HTDS)
StocksHaven Investments takes a look at Hard to Treat Diseases, Inc. (PINK:HTDS) which may profit from the upcoming flu season
New Credit Card Law to Take Effect in 2010 (NYSE:V) (NYSE:MA)
The following article was written and contributed by a highly regarded investor and member within the StocksHaven Investments community, Jeff Lawson: With the recent passage and signing of the Credit Card Accountability, Responsibility, and Disclosure Act of 2009 (the Credit CARD Act), some chang...
Shares Seem Undervalued – Elan Corporation (NYSE:ELN)
Shares of the neuroscience-based biotechnology company look to be at a favourable price point (NYSE:ELN)
Playing With Fire – ARDM (OTC:ARDM)
Aradigm Corporation (Public, OTC:ARDM) Aradigm is a company with a lot of positive long-term gains, especially with regards to its product pipeline involving the inhaled Cipro product (ILCH) for BE and CF, however the short-term play is a very different story. This company lacks visibility and the ability to fully utilize press release syndication to maximize potential reach for investors, and also engages in massive dilution in order to maintain ongoing operations. Moreover, the financial position also suffers as the company is enduring a heavy amount of cash burn every year with zero revenues as of Q1 (Mar´09). There is also a big question mark when it comes to partnerships — who will step up to the plate and infuse the cash which is so badly sought after?
Sky High Potential – TerreStar Corp. (NASDAQ:TSTR)
The Launching of TerreStar-1 Looks to Propel TerreStar Corp. (NASDAQ: TSTR) for Financial Success
Why MuGard Will Be Successful
StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which hopes its drug, MuGard will be a big hit in Europe.
BioElectronics Corp. (OTC:BIEL) - A Doubled Edged Sword
StocksHaven Investments news portal takes a closer look at BioElectronics Corporation (OTC:BIEL), which hopes its drug, Allay (TM) - Menstrual Pain Therapy will turn the business' fortunes around and make way for a positive future ahead.
Nephros (OTC:NEPH): Three FDA Decisions, One Company
Nephros prepares for a year thats bound to feel like a roller coaster ride.
Third Time´s A Charm For Nuvo Research (TSE:NRI)
Novel Osteoarthritis Treatment by Nuvo (TSE:NRI) confident of FDA approval.
Hot FDA Trade: BioDelivery Sciences International
BioDelivery (NASDAQ:BDSI) Investors Confident Pre-FDA Announcement
Gaining Momentum - Access Pharmaceuticals (OTC:ACCP)
StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which looks ahead for a very successful year with MuGard and their multi-national product distribution deals and partnerships. Note: StocksHaven Investments is up 121% from the initial buy on May/8/09 of(AMEX:HEB)
Identifying Fact vs. Fiction on Hermispherx´s Ampligen
StocksHaven Investments' reader analyzes and deciphers the latest information on Hemispherx (AMEX:HEB) Ampligen
Hemispherx Ampligen Combats H5N1
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), and its drug Ampligen which is used as an adjuvant to combat H5N1 (Swine Flu)
Post Approval Hemispherx Ampligen PPS Evaluation
StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), and analyzes the potential PPS should Ampligen see FDA approval in the coming weeks.
Consumer Confidence Index Encourages Economic Rebound
StocksHaven Investments news portal takes a closer look at the Consumer Confidence Index as of May 2009, which displays high optimism towards a faster than expected economic recovery.

Articles by Michael Vlaicu From Other Sources

Second Time´s a Charm for Somaxon (NASDAQ:SOMX)
published in Second Time´s a Charm for Somaxon (NASDAQ:SOMX)

Contact Michael Vlaicu

Your Name
Your Email Address
Your Phone Number
Comments

Mailing List

Sign up here to receive periodic updates from this author.

Your Name
Your Email Address